Mario Melazzini

1.2k total citations
29 papers, 535 citations indexed

About

Mario Melazzini is a scholar working on Neurology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mario Melazzini has authored 29 papers receiving a total of 535 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Neurology, 8 papers in Genetics and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mario Melazzini's work include Amyotrophic Lateral Sclerosis Research (12 papers), Neurogenetic and Muscular Disorders Research (8 papers) and Parkinson's Disease Mechanisms and Treatments (3 papers). Mario Melazzini is often cited by papers focused on Amyotrophic Lateral Sclerosis Research (12 papers), Neurogenetic and Muscular Disorders Research (8 papers) and Parkinson's Disease Mechanisms and Treatments (3 papers). Mario Melazzini collaborates with scholars based in Italy, Switzerland and Germany. Mario Melazzini's co-authors include Christian Lunetta, Eleonora Maestri, Massimo Corbo, Gabriele Mora, Caterina Bendotti, Dario Alimonti, Alessandra Pasini, Silvia Garbelli, Stefania Mantovani and Cesare Perotti and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Mario Melazzini

25 papers receiving 521 citations

Peers

Countries citing papers authored by Mario Melazzini

Since Specialization

Citations

This map shows the geographic impact of Mario Melazzini's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mario Melazzini with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mario Melazzini more than expected).

Fields of papers citing papers by Mario Melazzini

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mario Melazzini. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mario Melazzini. The network helps show where Mario Melazzini may publish in the future.

Co-authorship network of co-authors of Mario Melazzini

This figure shows the co-authorship network connecting the top 25 collaborators of Mario Melazzini. A scholar is included among the top collaborators of Mario Melazzini based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mario Melazzini. Mario Melazzini is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Reduced Emergency Department Visits and Hospitalizations in Infants after Universal Respiratory Syncytial Virus Immunization, Italy, 2024–25 2026 ·Emerging infectious diseases ·(unknown), (unknown), E. Pigozzi, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Mario Melazzini, (unknown), (unknown), (unknown)	0
2	The positive impact on translational research of Fondazione italiana di ricerca per la Sclerosi Laterale Amiotrofica (AriSLA), a non-profit foundation focused on amyotrophic lateral sclerosis. Convergence of ex-ante evaluation and ex-post outcomes when goals are set upfront 2023 ·SHILAP Revista de lepidopterología ·Stefania Guareschi, (unknown), Danila Baldessari, Silvia Pozzi, (unknown), Mario Melazzini, Anna Ambrosini	0
3	A phase I/IIa clinical trial of autologous hematopoietic stem cell transplantation in amyotrophic lateral sclerosis 2022 ·Journal of Neurology ·Christian Lunetta, Andrea Lizio, Corrado Cabona, Francesca Gerardi, Valeria Sansone, Massimo Corbo, Carlo Scialò, Emanuele Angelucci, Francesca Gualandi, Paola Marenco, Giovanni Grillo, Roberto Cairoli, Clara Cesana, Riccardo Saccardi, Mario Melazzini, Gianluigi Mancardi, Claudia Caponnetto	5
4	Management and outcomes of post-acute COVID-19 patients in Northern Italy 2020 ·European Journal of Internal Medicine ·Michele Vitacca, Giovanni Battista Migliori, Antonio Spanevello, Mario Melazzini, Nicolino Ambrosino, Piero Ceriana, Francesco Fanfulla, Alberto Braghiroli, C. Fracchia, Bruno Balbi	14
5	Determinants of price negotiations for new drugs. The experience of the Italian Medicines Agency 2019 ·Health Policy ·(unknown), (unknown), (unknown), Sara Antignani, (unknown), Ida Fortino, Mario Melazzini, Francesco Trotta, Giovanni Tafuri, Claudio Jommi	34
6	The new frontiers of rehabilitation medicine in people with chronic disabling illnesses 2018 ·European Journal of Internal Medicine ·Domenico Scrutinio, Anna Giardini, Luca Chiovato, Antonio Spanevello, Michele Vitacca, Mario Melazzini, G. Giorgi	10
7	Accesso precoce al mercato: dalle approvazioni condizionate di EMA agli accordi negoziali particolari di AIFA 2018 ·Global & Regional Health Technology Assessment ·(unknown), Claudio Jommi, Armando A. Genazzani, Sara Antignani, Simona Montilla, Mario Melazzini	2
8	The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: A national real‐life experience 2017 ·Liver International ·Silvia Martini, Maria Francesca Donato, Chiara Mazzarelli, Maria Rendina, Ubaldo Visco‐Comandini, (unknown), Alice Gianstefani, S. Fagiuoli, Mario Melazzini, Simona Montilla, Luca Pani, (unknown), Pierluigi Russo, Maria Paola Trotta, Paola Carrai, Paolo Caraceni, (unknown)	8
9	Development of advanced therapies in Italy: Management models and sustainability in six Italian cell factories 2016 ·Cytotherapy ·Giuseppe Gaipa, Martino Introna, Josée Golay, Maria Luisa Nolli, Giuliana Vallanti, Eugenio Parati, Rosaria Giordano, Luca Romagnoli, Mario Melazzini, Andrea Biondi, Ettore Biagi	6
10	Amyotrophic Lateral Sclerosis Survival Score (ALS-SS): A simple scoring system for early prediction of patient survival 2015 ·Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration ·Christian Lunetta, Andrea Lizio, Mario Melazzini, Eleonora Maestri, Valeria Sansone	27
11	Amyotrophic lateral sclerosis in pregnancy is associated with a vascular endothelial growth factor promoter genotype 2014 ·European Journal of Neurology ·Christian Lunetta, Valeria Sansone, Silvana Penco, Lorena Mosca, Claudia Tarlarini, Francesca Avemaria, Eleonora Maestri, Mario Melazzini, G. Meola, Massimo Corbo	10
12	Aggressiveness, sexuality, and obsessiveness in late stages of ALS patients and their effects on caregivers 2012 ·Amyotrophic Lateral Sclerosis ·Anna Maria Marconi, Giulia Meloni, (unknown), Christian Lunetta, (unknown), Mario Melazzini, Paolo Banfi, Gabriella Rossi, Massimo Corbo	16
13	Wide phenotypic spectrum of the TARDBP gene: homozygosity of A382T mutation in a patient presenting with amyotrophic lateral sclerosis, Parkinson's disease, and frontotemporal lobar degeneration, and in neurologically healthy subject 2012 ·Neurobiology of Aging ·Lorena Mosca, Christian Lunetta, Claudia Tarlarini, Francesca Avemaria, Eleonora Maestri, Mario Melazzini, Massimo Corbo, Silvana Penco	39
14	Mutation in the senataxin gene found in a patient affected by familial ALS with juvenile onset and slow progression 2011 ·Amyotrophic Lateral Sclerosis ·Francesca Avemaria, Christian Lunetta, Claudia Tarlarini, Lorena Mosca, Eleonora Maestri, Alessandro Marocchi, Mario Melazzini, Silvana Penco, Massimo Corbo	20
15	The frail person and his caregiver: cure, care or simultaneous care? A conceptual article 2011 ·Michele Vitacca, (unknown), (unknown), Mario Melazzini	7
16	Consistent bone marrow-derived cell mobilization following repeated short courses of granulocyte–colony-stimulating factor in patients with amyotrophic lateral sclerosis: results from a multicenter prospective trial 2010 ·Cytotherapy ·Corrado Tarella, Sergio Rutella, Francesca Gualandi, Mario Melazzini, Rosanna Scimè, Mario Petrini, Cristina Moglia, Marco Ulla, Paola Omedè, Vincenzo La Bella, Massimo Corbo, Vincenzo Silani, Gabriele Siciliano, Gabriele Mora, Claudia Caponnetto, Mario Sabatelli, Adriano Chiò	32
17	Immune system alterations in sporadic amyotrophic lateral sclerosis patients suggest an ongoing neuroinflammatory process 2009 ·Journal of Neuroimmunology ·Stefania Mantovani, Silvia Garbelli, Alessandra Pasini, Dario Alimonti, Cesare Perotti, Mario Melazzini, Caterina Bendotti, Gabriele Mora	143
18	Repeated Courses of Bone Marrow-Derived Cell Mobilization Induced by Granulocyte-Colony Stimulating Factor (G-CSF) in Amyotrophic Lateral Sclerosis: Interim Analysis of a Prospective Multicenter Trial. 2007 ·Blood ·Corrado Tarella, Mario Melazzini, Mario Petrini, Giuseppe Leone, Rosanna Scimè, Davide Soligo, Francesca Gualandi, Cristina Moglia, Gianluigi Mancardi, Vincenzo Silani, Vincenzo La Bella, Pietro Tonali, Gabriele Siciliano, Gabriele Mora, Adriano Chiò	0
19	Asbestos-induced peritoneal mesothelioma in a construction worker. 2003 ·Environmental Health Perspectives ·R. Fonte, (unknown), Mario Melazzini, M. Scelsi, (unknown), Stefano M. Candura	7
20	Chronic myelogenous leukemia following radiotherapy and chemotherapy for non-Hodgkin lymphoma. 1991 ·PubMed ·Mario Cazzola, Gaetano Bergamaschi, Mario Melazzini, Luisa Ponchio, Vittorio Rosti, Enrico Molinari	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact